Cell type-specific association of hypoxia-inducible factor-1α (HIF-1α) protein accumulation and radiobiologic tumor hypoxia

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 4, 2004, Pages 1242-1250

  Vordermark, Dirk ^a   Katzer, Astrid ^a   Baier, Kurt ^a   Kraft, Peter ^a   Flentje, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cellular radiation resistance; HIF protein; Hypoxia

Indexed keywords

BIOMARKERS; DOSIMETRY; PATIENT TREATMENT; PROTEINS; RADIOTHERAPY; TUMORS;

REOXYGENATIONS; TRANSCRIPTION FACTORS;

CELLS;

CELL EXTRACT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN;

ARTICLE; ASSOCIATION; CANCER CELL CULTURE; CELL HYPOXIA; CELL NUCLEUS; CELL TYPE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR CLONING; PHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOLOGY; RADIOSENSITIVITY; REOXYGENATION; SURVIVAL; TIME;

CELL HYPOXIA; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FIBROSARCOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHARYNGEAL NEOPLASMS; RADIATION TOLERANCE; TRANSCRIPTION FACTORS; TUMOR STEM CELL ASSAY;

EID: 1542316344     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.11.030     Document Type: Article

References (32)

1. Begg A.C. Is HIF-1α a good marker for tumor hypoxia? Int J Radiat Oncol Biol Phys. 56:2003;917-919.
2. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer. 2:2002;38-47.
3. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia: Predictors of clinical radiation resistance? Strahlenther Onkol 2003;179:801-811
4. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1alpha A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2001;2911-2916.
5. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-inducible factor (HIF 1A and HIF 2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 53:2002;1192-1202.
6. Hui E.P., Chan A.T., Pezzella F., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 8:2002;2595-2604.
7. Nordsmark M., Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 57:2000;39-43.
8. 2 histography in patients with advanced head and neck cancer. Strahlenther Onkol. 177:2001;462-468.
9. Vordermark D., Brown J.M. Evaluation of hypoxia-inducible factor-1α (HIF-1α) as an intrinsic marker of tumor hypoxia in U87 MG human glioblastoma In-vitro and xenograft studies. Int J Radiat Oncol Biol Phys. 56:2003;1184-1193.
10. Steel GG. Basic clinical radiobiology. 2nd ed. London: Arnold; 1997. p. 158-159
11. Jiang BH, Semenza GL, Bauer C, et al. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996;271:C1172-C1180
12. Popple R., Ove R., Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 54:2002;921-927.
13. von Pawel J., von Roemeling R., Gatzemeier U., et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 18:2000;1351-1359.
14. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 52:2002;769-778.
15. Shibata T., Giaccia A.J., Brown J.M. Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 4:2002;40-48.
16. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 20:2002;680-687.
17. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62:2002;7066-7074.
18. Nordsmark M., Loncaster J., Aquino-Parsons C., et al. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol. 67:2003;35-44.
19. Nordsmark M., Alsner J., Keller J., et al. Hypoxia in human soft tissue sarcomas Adverse impact on survival and no association with p53 mutations. Br J Cancer. 84:2001;1070-1075.
20. Jewell U.R., Kvietikova I., Scheid A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15:2001;1312-1314.
21. Zhong H., Mabjeesh N., Willard M., et al. Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett. 181:2002;233-238.
22. Gross M.W., Karbach U., Groebe K., et al. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer. 61:1995;567-573.
23. Lee J., Siemann D., Koch C.J., et al. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 67:1996;372-378.
24. Zölzer F., Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys. 54:2002;910-920.
25. Hall EJ. Radiobiology for the radiologist. 3rd ed. Philadelphia: J. B. Lippincott; 1988. p. 137-160
26. Vukovic V., Haugland H.K., Nicklee T., et al. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res. 61:2001;7394-7398.
27. Jansen H.L., Haustermans K.M., Sprong D., et al. HIF-1alpha, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys. 54:2002;1537-1549.
28. Labrecque S., Matlashewski G.J. Viability of wild type p53-containing and p53-deficient tumor cells following anticancer treatment The use of human papillomavirus E6 to target p53. Oncogene. 11:1995;387-392.
29. Kim M.S., Li S.L., Bertolami C.N., et al. State of p53, Rb and DCC tumor suppressor genes in human cancer cell lines. Anticancer Res. 13:1993;1405-1413.
30. Geiser A.G., Anderson M.J., Stanbridge E.J. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49:1989;1572-1577.
31. Hoa M., Davis S.L., Ames S.J., et al. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res. 62:2002;7154-7156.
32. Lando D., Gorman J.J., Whitelaw M.L., et al. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparyginyl hydroxylation. Eur J Biochem. 270:2003;781-790.